期刊
JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE
卷 9, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/jcdd9070225
关键词
diabetes; gliflozins; heart failure; SGLT2; sodium-glucose cotransporter-2 inhibitors
SGLT2 inhibitors are effective in reducing glycemia and have cardioprotective and nephroprotective effects. Recent studies have shown that these inhibitors can significantly reduce the risk of hospitalization and death in heart failure, regardless of the patient's diabetes status.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are currently the second-line pharmacotherapy in type 2 diabetes, particularly through their effectiveness in reducing glycemia, but also due to their cardioprotective and nephroprotective effects. In light of surprisingly satisfactory results from large, randomized trials on gliflozins, SGLT2 received the highest recommendation (Class IA) with the highest level of evidence (A) in the treatment algorithm for HF with reduced LVEF in recent ESC HF guidelines. This great breakthrough in the treatment of HF is due to different mechanisms of action of gliflozins that are reported to be able to change the natural course of HF by reducing the risk of both hospitalization and death. They are recommended regardless of the patient's diabetes status. This review summarizes the up-to-date literature on their beneficial and pleiotropic impact on the cardiovascular system.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据